佐力藥業(300181.SZ):未來力爭把烏靈膠囊打造成20億規模的大品種
格隆匯1月17日丨佐力藥業(300181.SZ)披露投資者關係活動記錄表顯示,湖州市提出要將生物醫藥打造成千億級的產業,公司作為鏈主型企業,也提出了未來營收奮進百億的戰略目標。公司最核心的還是醫藥製造業,尤其是烏靈系列和百令系列,其中烏靈膠囊會繼續加強對醫院的覆蓋,深耕已經覆蓋的醫院和科室,同時強化招商、OTC和互聯網端的開發,公司未來力爭把烏靈膠囊打造成20億規模的大品種;靈澤片主要用於治療良性前列腺增生症患者的夜尿頻多,效果較為明顯,臨牀上認可度較高,靈澤片自從2018年進入國家基藥以來,銷售勢頭很好,靈澤片第一步的銷售目標是5億,未來力爭打造成10億的大品種;靈蓮花顆粒主要致力於改善綜合女性更年期症狀,轉為OTC品種後公司未來會通過互聯網的銷售模式來拓展銷售量;百令系列公司現在擁有百令片和百令膠囊,蟲草菌粉製劑現有幾十億的市場,市場容量廣闊,希望通過一系列營銷措施,能夠把我們的百令系列打造成10億規模的品種。
中藥飲片和中藥配方顆粒方面,浙江省大概有大幾十億的飲片市場,我們每年都有一定的增幅,處於穩健發展的狀態,未來會繼續以大杭州為中心深耕省內市場,進一步做強;據多家機構預測,配方顆粒市場未來可達千億級,公司也會進一步強化營銷,努力藉此機會,開拓全國市場。同時,公司還設立了孫公司浙江佐力醫藥有限公司,做大優勢產品的商業業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.